Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal 2012

Conference Call Scheduled for Tuesday, November 15, 2011


NORTHVALE, N.J., Nov. 14, 2011 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral controlled release product formulations, announced results for the fiscal second quarter ended September 30, 2011.

For the second quarter, consolidated revenues were $274,132, a decrease of 72% compared with last year's second quarter, with revenues being earned from diversified revenue streams that included the manufacturing and sale of the Phentermine and Lodrane D® products both launched this fiscal year, and lab service revenues and residual royalties related to the discontinued extended release Lodrane 24 and Lodrane 24D® products.

Operating losses increased to $591,602 from last year's second quarter operating loss of $136,807. The increase in operating losses was mainly the result of a significant decrease in revenues relating to the removal of the sustained release Lodrane products, combined with increased product development costs being incurred in connection with Elite's efforts to bring new products to the market.

The first few months of sales from the newly launched phentermine and Lodrane D® products were not sufficient to offset the loss of revenue and income from the discontinued extended release Lodrane products. Elite, however, does expect that the revenues from these newly launched products will continue to grow and we anticipate approvals soon for the three products currently under review by the FDA. In addition, we are expecting revenues to begin shortly from the first of the three contract manufacturing opportunities.

 GAAP net income, including non-cash revenues and expenses relating to the accounting treatment of preferred share derivatives and the fair value of warrant derivatives, was $13,919,321, or $0.06 basic net income per share and $0.03 fully diluted net income per share.

Cash flow from operations was a negative $230,333 for the first two quarters of fiscal 2011, compared to a positive operating cash flow of $354,788 for last year's first two quarters. Net cash flow for the first two quarters, inclusive of cash used in investing and financing activities, was a negative $486,777. Cash as of September 30, 2011 was $1,339,078.

"Unfortunately this past quarter demonstrated the negative impact on revenue and profits from the loss of Lodrane extended-release manufacturing and sale while we are still in the early phases of launching our new product pipeline. We currently manufacture two products and as we have discussed before, we expect to be manufacturing additional products both for our own account and on a contract basis. It is our expectation that these additional products will enable the company to achieve positive cash flow from operations over time" stated Jerry Treppel, Elite Chairman & CEO.

The Company will host a conference call to discuss the results of operations and provide an update on recent business developments on Tuesday, November 15, 2011 at 2:00 PM EST. Company executives will also conduct a question and answer session following their remarks.

To access the conference call:              

Domestic callers: (800) 346-7359
International callers: (973) 528-0008
Conference Entry Code: 98840

A digital telephone replay will be available approximately one hour after the conclusion of the call for two weeks until November 29, 2011 by dialing:                          

Domestic callers: (800) 332-6854
International callers: (973) 528-0005
Conference entry code: 98840

Financial Statements

 
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
 
ASSETS    
  September 30, 2011 March 31, 2011
  (Unaudited) (Audited)
CURRENT ASSETS    
Cash and cash equivalents $1,339,078 $1,825,858
Accounts receivable, (net of allowance for doubtful accounts of zero) 252,659 571,667
Inventories (net of allowance of $93,338 and $ 1,047,456, respectively) 382,239 616,362
Prepaid expenses and other current assets 104,518 133,472
     
Total current assets 2,078,494 3,147,359
     
PROPERTY AND EQUIPMENT, net of accumulated depreciation and
amortization of $4,427,377 and $4,189,618, respectively
4,243,696 4,118,274
     
INTANGIBLE ASSETS – net of accumulated amortization of zero 613,833 597,556
     
OTHER ASSETS    
Investment in Novel Laboratories Inc. 3,329,322 3,329,322
Security deposits 13,725 28,377
Restricted cash – debt service for EDA bonds 287,131 291,420
EDA Bond offering costs, net of accumulated amortization    
 of $85,964 and $78,898, respectively 268,488 275,554
     
Total other assets 3,898,666 3,924,673
     
TOTAL ASSETS $10,834,689 $11,787,862
     
     
LIABILITIES AND STOCKHOLDERS' DEFICIT     
  September 30, 2011 March 31, 2011
  (Unaudited) (Audited)
CURRENT LIABILITIES    
EDA Bonds payable $3,385,000 $3,385,000
Short term loans and current portion of long-term debt 13,517 13,105
Accounts payable and accrued expenses 937,285 935,797
Customer Deposits --- 39,400
Deferred Revenues – Current 13,333 13,333
Preferred share derivative interest payable 124,370 282,680
Total Current Liabilities 4,473,505 4,669,315
     
LONG TERM LIABILITIES    
Deferred Revenues 172,224 178,890
Other long term liabilities 75,163 75,463
Derivative Liability – Preferred Shares 16,172,177 14,192,329
Derivative Liability – Warrants 13,629,540 10,543,145
Total Long-Term Liabilities 30,049,104 24,989,827
     
Total Liabilities 34,522,609 29,659,142
     
COMMITMENTS AND CONTINGENCIES:    
     
STOCKHOLDERS' DEFICIT     
     
     
Common Stock – par value of $0.001, Authorized 355,516,558
Issued and outstanding – 254,779,074 shares and 180,545,657 shares,
respectively
254,780 180,546
     
Additional paid-in capital 108,039,275 97,116,044
     
Accumulated deficit (131,675,134) (114,861,029)
     
Treasury stock, at cost (100,000 common shares) (306,841) (306,841)
     
Total Stockholders' Deficit  (23,687,920) (17,871,280)
     
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT  $10,834,689 $11,787,862
 
 
 
ELITE PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
     
   
  Three Months Ended
  September 30, 
  2011 2010
  (unaudited) (unaudited)
REVENUES:    
Manufacturing Revenues $78,294 $767,341
Royalties and Profit Splits 100,069 169,901
Lab Fee Revenues 95,769 57,404
Total Revenues 274,132 994,646
     
Cost of Revenues  76,331 565,624
Gross Profit 197,801 429,022
     
OPERATING EXPENSES    
Research and Development 198,212 150,436
General and Administrative 476,897 379,104
Non-cash compensation through issuance of stock options and warrants 6,113 10,329
Depreciation and amortization 108,181 25,960
Total Operating Expenses 789,403 565,829
     
LOSS FROM OPERATIONS (591,602) (136,807)
     
OTHER INCOME / (EXPENSES):    
Interest expense (57,931) (57,737)
Change in fair value of outstanding warrant derivatives 10,497,037 900,047
Change in fair value of preferred share derivatives 4,196,187 1,505,333
Interest expense attributable to dividends accrued to preferred share derivative liabilities (124,370) (306,440)
Discount in Series E issuance attributable to beneficial conversion features --- (39,132)
Total Other Income / (Expense) 14,510,923 2,002,071
     
INCOME BEFORE PROVISION FOR INCOME TAXES 13,919,321 1,865,264
     
Provision for Income Taxes --- 1,040
     
NET INCOME $13,919,321 $1,864,224
     
NET INCOME ATTRIBUTABLE TO COMMON SHAREHOLDERS $13,919,321 $1,864,224
     
NET INCOME PER SHARE    
 BASIC $0.06 $0.02
 DILUTED $0.03 $0.01
     
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDINGS    
 BASIC 248,247,253 92,367,680
 DILUTED 454,162,476 299,999,783

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. Elite has four ANDA products partnered with TAGI Pharma; one ANDA has launched, two ANDAs are in the process of a manufacturing site transfer and an additional ANDA is currently under review by the FDA. Elite also manufactures Lodrane D® and receives royalties for Lodrane D®, an allergy product partnered with ECR Pharmaceuticals ("ECR"), a wholly owned subsidiary of Hi-Tech Pharmacal ("Hi-Tech"). Elite's lead pipeline products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also has partnered with Mikah Pharma to develop a new product and with Hi-Tech Pharmacal to develop an intermediate for a generic product. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.

The Elite Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8737

This news release contains forward-looking statements, including those related to the preliminary nature of the clinical program results and the potential for further product development, that involve known and unknown risks, delays, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of the companies to be materially different from the results, performance or other expectations implied by these forward-looking statements. In particular, because substantial future testing will be required prior to approval, the results described above may not be supported by additional data or by the results of subsequent trials. These risks and other factors, including the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, and intellectual property protections and defenses, are discussed in Elite's filings with the Securities and Exchange Commission such as the 10K, 10Q and 8K reports. Elite undertakes no obligation to update any forward-looking statements.



            

Kontaktdaten

GlobeNewswire